Neonati prematuri

Registrazione, rimborso e uso appropriato dei farmacinon sono sinonimi: il caso del palivizumab

A. Addis, M. Bonati, F. Marchetti

2016/8 — pag. 507-512

Respiratory syncytial virus (RSV) is a common reason for hospitalization of infants. Data from clinical trials showed that palivizumab reduced RSV hospitalization rates for premature infants. However, according to different sources of information s...

La carenza di ferro nel neonato pretermine

V. Guastalla, M.C. Pellegrin, F. Rovere, R. Davanzo

2015/5 — pag. 298-305

Iron deficiency is the most common micronutrient deficiency worldwide. Preterm infants are a special risk group, because of lower total body iron at birth, rapid catch-up growth and uncompensated phlebotomy losses. Recent scientific literature sugg...

L’ossigenoterapia ad alti flussi in neonatologia

G. Maffei, R. Magaldi

2013/1 — pag. 39-41

The Authors reviewed the literature on the effects of heated humidified high flow nasal cannula (HHHFNC) treatment in preterm infants. The HHHFNC delivers a continuous distending pressure (CDP) in smaller infants proportional to the flow that is ex...

Il trattamento del neonato con desametasone altera lo sviluppo della corteccia cerebrale

G. Bartolozzi

2001/4

Palivizumab: un anticorpo monoclonale umanizzato contro il virus respiratorio sinciziale

L. De Seta, G. Orso

1999/8 — pag. 491-494

Respiratory Syncytial Virus (RSV) is the main cause of respiratory infections in the first years of life. Preterm infants and those affected by broncopulmonary dysplasia (BPD) represent the categories at highest risk of severe RSV infections. Paliv...